Finoso Pharma, Criti Tech form JV for tech designingIllustrative image – not actual.

Finoso Pharma and the US based Criti Tech Inc have formed a 50:50 JV — Finotech Pharma.

The JV will work on providing advanced technology for designing extremely small particles required in drug-making. The therapeutic areas to be focussed by Finotech Pharma would be oncology and lung diseases, among others. Three key customers were already identified for Fenotech and it would scout for more customers in the domestic and foreign markets.
← All latest storiesBack to top →